Tag: KDC-MN-367

  • Abaloparatide

    Synthetic parathyroid hormone-related protein (PTHrP) analog and selective PTH1 receptor agonist with preferential RG-conformation binding

    A 34-amino-acid synthetic analog of human parathyroid hormone-related protein (1-34) engineered for selective activation of the RG conformation of the PTH type 1 receptor, producing transient osteoanabolic cAMP signaling with reduced bone resorption and hypercalcemia relative to teriparatide, approved for the treatment of osteoporosis in postmenopausal women and men at high fracture risk.

    Abstract

    Abaloparatide (BA058) is a synthetic 34-amino-acid peptide analog of human parathyroid hormone-related protein (PTHrP) (1-34) that acts as a selective agonist at the parathyroid hormone type 1 receptor (PTH1R), a class B G protein-coupled receptor expressed on osteoblasts and osteocytes. The compound was rationally designed to exploit conformational selectivity at PTH1R: abaloparatide binds the G protein-coupled RG conformation with an IC50 of approximately 0.20 nM and the G protein-independent R0 conformation with an IC50 of approximately 316 nM, yielding a 1,600-fold RG/R0 selectivity ratio that exceeds native PTHrP(1-36) (110-fold), native PTH(1-34) (12-fold), and the long-acting analog LA-PTH (2.2-fold). This selectivity produces a transient downstream cAMP signaling response following receptor activation, which, when delivered as a once-daily intermittent subcutaneous injection, preferentially stimulates osteoblast-mediated bone formation with lesser stimulation of osteoclast-mediated bone resorption and a lower incidence of hypercalcemia than teriparatide (recombinant PTH(1-34)), the first-in-class parathyroid hormone receptor agonist for osteoporosis.

    The compound shares 76% amino acid sequence homology with native PTHrP(1-34) and 41% homology with native PTH(1-34). The first 22 amino acids are identical to PTHrP(1-22); positions 23 through 34 carry eight substitutions, including an alpha-aminoisobutyric acid (Aib) residue at position 29, introduced to constrain the C-terminal alpha-helix and enhance peptide stability and receptor binding selectivity. The molecular formula is C174H300N56O49 with a molecular weight of approximately 3,960 daltons. Pharmacokinetics after subcutaneous dosing are characterized by rapid absorption (median Tmax approximately 0.51 hours), an absolute bioavailability of approximately 36%, a volume of distribution of approximately 50 liters, plasma protein binding of approximately 70%, and an elimination half-life of approximately 1 hour, with clearance proceeding through nonspecific proteolytic degradation to smaller peptide fragments followed by renal excretion.

    The subsequent ACTIVExtend trial demonstrated that sequential treatment with abaloparatide followed by alendronate maintained fracture risk reduction and further increased bone mineral density over a combined 43-month observation period. The ATOM trial extended efficacy to men with osteoporosis, demonstrating lumbar spine bone mineral density gains of 8.48% versus 1.17% on placebo at 12 months. The compound received United States Food and Drug Administration approval on April 28, 2017, for postmenopausal women with osteoporosis at high fracture risk (marketed as Tymlos), with an expanded indication for men with osteoporosis approved in December 2022. European Medicines Agency approval was granted in December 2022 under the trade name Eladynos. A transdermal solid microstructured transdermal system (sMTS) formulation is in clinical development as an alternative to subcutaneous injection. Treatment duration is limited to a cumulative lifetime maximum of 2 years owing to a dose- and time-dependent increase in osteosarcoma incidence observed in preclinical rodent carcinogenicity studies, a class effect shared with teriparatide.

    This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.